Odyssey Health
Odyssey Health Inc. is a specialty medical company focused on developing and commercializing life-saving medical products and health-related technologies. The company's mission is to address unmet medical needs through innovative solutions, including intranasal drugs for neurological conditions, cardiovascular mapping technology, and choking rescue devices. Odyssey aims to create, acquire, and advance unique assets and technologies with a focus on technological advantage, clinical utility, and market potential.
Industries
Nr. of Employees
small (1-50)
Odyssey Health
2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV 89102
Products
Intranasal brain-targeted neuroactive therapeutic (candidate for acute concussion treatment)
A fully synthetic neuroactive small-molecule formulation developed for intranasal administration with preclinical efficacy in concussion models, completed Phase I SAD/MAD safety studies, and a delivery system optimized to enhance brain exposure while minimizing systemic blood levels.
Intranasal neuroactive candidate for Niemann-Pick Type C (preclinical)
A first-in-class intranasal neurosteroid candidate developed for Niemann-Pick Type C disease with completed intranasal formulation and positive preclinical cell-culture and animal model signals and no observed drug-related toxicity in reported studies.
Point-of-care cardiac monitoring and screening system (prototype)
A portable cardiac monitoring and screening device under development intended to produce enhanced sensitivity cardiac measurements, 3D visualizations to supplement standard ECG outputs, and rapid web-based analysis for remote and home screening.
Mechanical choking rescue device (prototype)
A device under development intended to provide a non-pharmaceutical intervention for clearing airway obstruction in choking events.
Intranasal brain-targeted neuroactive therapeutic (candidate for acute concussion treatment)
A fully synthetic neuroactive small-molecule formulation developed for intranasal administration with preclinical efficacy in concussion models, completed Phase I SAD/MAD safety studies, and a delivery system optimized to enhance brain exposure while minimizing systemic blood levels.
Intranasal neuroactive candidate for Niemann-Pick Type C (preclinical)
A first-in-class intranasal neurosteroid candidate developed for Niemann-Pick Type C disease with completed intranasal formulation and positive preclinical cell-culture and animal model signals and no observed drug-related toxicity in reported studies.
Point-of-care cardiac monitoring and screening system (prototype)
A portable cardiac monitoring and screening device under development intended to produce enhanced sensitivity cardiac measurements, 3D visualizations to supplement standard ECG outputs, and rapid web-based analysis for remote and home screening.
Mechanical choking rescue device (prototype)
A device under development intended to provide a non-pharmaceutical intervention for clearing airway obstruction in choking events.
Services
Execution and oversight of Phase I SAD and MAD studies conducted in collaboration with contract research organizations and clinical trial networks, including randomized, double-blind, placebo-controlled designs and safety review committee oversight.
Execution and oversight of Phase I SAD and MAD studies conducted in collaboration with contract research organizations and clinical trial networks, including randomized, double-blind, placebo-controlled designs and safety review committee oversight.
Expertise Areas
- Intranasal drug delivery
- Neuropharmacology for traumatic brain injury
- Preclinical TBI models and behavioral pharmacology
- Early-phase clinical development (Phase I SAD/MAD)
Key Technologies
- Breath-propelled intranasal delivery devices
- Spray-dried nanoparticle formulations
- Heat-stable powder formulations
- Preclinical concussion/TBI animal models
News & Updates
Odyssey Health, Inc. provided an update on its Asset Purchase Agreement with Oragenics, Inc., including details about shares and cash involved, and strategic benefits of the transaction.
Odyssey Health's stock commenced trading on the OTCQB Market after up-listing from OTC Pink Market, marking a milestone in its development programs.
Odyssey announced the successful completion of all cohorts in its Phase I clinical trial for PRV-002, a drug to treat concussion, demonstrating safety and tolerability.
Odyssey announced positive safety results from the first group of patients dosed with PRV-002 in their Phase I clinical trial for concussion.
Odyssey Health, Inc. provided an update on its Asset Purchase Agreement with Oragenics, Inc., including details about shares and cash involved, and strategic benefits of the transaction.
Odyssey Health's stock commenced trading on the OTCQB Market after up-listing from OTC Pink Market, marking a milestone in its development programs.
Odyssey announced the successful completion of all cohorts in its Phase I clinical trial for PRV-002, a drug to treat concussion, demonstrating safety and tolerability.
Odyssey announced positive safety results from the first group of patients dosed with PRV-002 in their Phase I clinical trial for concussion.